K. Hoekman

403 total citations
11 papers, 323 citations indexed

About

K. Hoekman is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. Hoekman has authored 11 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. Hoekman's work include Cancer Treatment and Pharmacology (6 papers), Angiogenesis and VEGF in Cancer (5 papers) and Estrogen and related hormone effects (2 papers). K. Hoekman is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Angiogenesis and VEGF in Cancer (5 papers) and Estrogen and related hormone effects (2 papers). K. Hoekman collaborates with scholars based in Netherlands, United States and Belgium. K. Hoekman's co-authors include Herbert M. Pinedo, Bart C. Kuenen, Marcel Levi, Giuseppe Giaccone, A.K. Kakkar, Johannes Berkhof, Victor W.M. van Hinsbergh, Joost C.M. Meijers, P. Scigalla and G. Cropp and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

K. Hoekman

11 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Hoekman Netherlands 6 166 128 72 60 55 11 323
Susan B. Ingersoll United States 8 144 0.9× 144 1.1× 67 0.9× 55 0.9× 12 0.2× 21 516
Carmen Julia Tartari Italy 11 227 1.4× 108 0.8× 36 0.5× 97 1.6× 56 1.0× 25 421
Silvana Vignati Italy 7 257 1.5× 184 1.4× 152 2.1× 218 3.6× 27 0.5× 9 489
W D Figg United States 5 147 0.9× 99 0.8× 96 1.3× 222 3.7× 5 0.1× 6 357
Anri Tienhaara Finland 10 167 1.0× 161 1.3× 27 0.4× 24 0.4× 5 0.1× 20 412
Dongmin Chang China 13 393 2.4× 184 1.4× 260 3.6× 69 1.1× 20 0.4× 25 627
Chiara Bennati Italy 13 180 1.1× 406 3.2× 158 2.2× 502 8.4× 32 0.6× 40 632
Sophie L. Corthals Netherlands 7 208 1.3× 259 2.0× 65 0.9× 34 0.6× 12 0.2× 12 556
Mitchell J. Geer United States 7 243 1.5× 108 0.8× 33 0.5× 38 0.6× 6 0.1× 9 388
Kaoru Takami Japan 11 197 1.2× 239 1.9× 71 1.0× 60 1.0× 13 0.2× 24 469

Countries citing papers authored by K. Hoekman

Since Specialization
Citations

This map shows the geographic impact of K. Hoekman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Hoekman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Hoekman more than expected).

Fields of papers citing papers by K. Hoekman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Hoekman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Hoekman. The network helps show where K. Hoekman may publish in the future.

Co-authorship network of co-authors of K. Hoekman

This figure shows the co-authorship network connecting the top 25 collaborators of K. Hoekman. A scholar is included among the top collaborators of K. Hoekman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Hoekman. K. Hoekman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Reyners, Anna K.L., Willem M. Smit, Michael Schaapveld, et al.. (2009). Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study. Journal of Clinical Oncology. 27(15_suppl). 5545–5545. 1 indexed citations
3.
Langenberg, Marlies H.G., Carla M. van Herpen, Johann S. de Bono, et al.. (2008). Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib. Journal of Clinical Oncology. 26(15_suppl). 3555–3555. 14 indexed citations
4.
5.
Hensbergen, Yvette van, Bart C. Kuenen, P. J. van Diest, et al.. (2004). A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour. Journal of Clinical Pathology. 57(5). 536–538. 3 indexed citations
6.
Kuenen, Bart C., Marcel Levi, Joost C.M. Meijers, et al.. (2003). Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416. Journal of Clinical Oncology. 21(11). 2192–2198. 91 indexed citations
7.
Nanayakkara, Prabath W.B., J. van Doorn, F.G. van den Berg, et al.. (2002). Treatment of haemangiopericytoma-associated hypoglycaemia with embolisation. European Journal of Internal Medicine. 13(5). 340–343. 9 indexed citations
8.
Kuenen, Bart C., Lee S. Rosen, Egbert F. Smit, et al.. (2002). Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. Journal of Clinical Oncology. 20(6). 1657–1667. 113 indexed citations
9.
Hoekman, K., et al.. (2001). Phase II study of paclitaxel (taxol, gemcitabine, and cisplatin for patients with advanced ovarian cancer). European Journal of Cancer. 37. S319–S319. 2 indexed citations
10.
Peters, Godefridus J., Michiel de Bruin, Masakazu Fukushima, et al.. (2000). Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor.. PubMed. 486. 291–4. 1 indexed citations
11.
Hoekman, K., John Wagstaff, Jan B. Vermorken, et al.. (1994). [Primary high-dose chemotherapy with hematopoietic growth factors followed by surgery and radiotherapy in stage III breast carcinoma; a Phase II study in 15 patients].. PubMed. 138(21). 1069–73. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan B. Ingersoll Breakdown of academic impact, for papers by Carmen Julia Tartari Breakdown of academic impact, for papers by Silvana Vignati Breakdown of academic impact, for papers by W D Figg Breakdown of academic impact, for papers by Anri Tienhaara Breakdown of academic impact, for papers by Dongmin Chang Breakdown of academic impact, for papers by Chiara Bennati Breakdown of academic impact, for papers by Sophie L. Corthals Breakdown of academic impact, for papers by Mitchell J. Geer Breakdown of academic impact, for papers by Kaoru Takami
Rankless by CCL
2026